Researchers Identify Immunologic Basis of ‘Exceptional Survival’ in Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
Patients with pancreatic cancer who had tumors with a combination of the highest neoantigen number and the most abundant CD8-positive T-cell infiltrates survived significantly longer than those without those tumor characteristics, according to study results.

“These results are exciting — particularly in the field of pancreatic cancer, which can be a very difficult diagnosis and treatment for a patient to contend with,” Vinod P. Balachandran, MD, surgical oncologist and member of the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, said in a press release.  Read more . . .